In Quebec, where one in four adults is obese, the current cost of these new drugs (approximately $500 per month) would involve an annual expenditure of several hundred million dollars (in the United States the situation is even worse: the cost of a 72-week course of tirzepatide (15 mg/week) is approximately US$17,000, while the 68-week treatment with semaglutide (2.4 mg/week) is nearly US$23,000!)
With advancing age, cellular NAD levels decline significantly through three main mechanisms: reduced synthesis (decreased NAMPT), increased catabolism (CD38 hyperactivation under inflammaging conditions) and excessive consumption by DNA repair systems. Intravenous administration of NAD or its precursors such as NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) aims to restore a more youthful biosynthetic and reparative capacity to ageing cells
Coskun T, Urva S, Roell WC, et al
In my clinical experience, the pattern is similar for both medications: Weeks 14: Nausea is most common, especially after meals
*Cardiovascular Disease*: L-Carnitine Injection may be used to support heart health and reduce the risk of cardiovascular disease